Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

[Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results].

Autor: Boyko AN; Pirogov National Medical Research University, Moscow, Russia.; Federal Center for Brain Research and Neurotechnologies, Moscow, Russia., Bakhtiyarova KZ; Kuvatov Republican Clinical Hospital, Ufa, Russia., Boyko OV; Federal Center for Brain Research and Neurotechnologies, Moscow, Russia., Dudin VA; Center for Cardiology and Neurology, Kirov, Russia., Zaslavskii LG; Leningrad Regional Clinical Hospital, St. Petersburg, Russia., Malkova NA; Regional Clinical Hospital, Novosibirsk, Russia., Parshina EV; Semashko Regional Clinical Hospital, Nizhny Novgorod, Russia., Poverennova IY; Seredavin Regional Clinical Hospital, Samara, Russia., Sivertseva SA; Medical and Sanitary Unit «Neftyanik», Tyumen, Russia., Totolyan NA; Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russia., Shchur SG; Filatov Moscow City Clinical Hospital No. 15, Moscow, Russia., Khabirov FA; Republican Clinical Neurological Center, Kazan, Russia., Goncharova ZA; Rostov State Medical University, Rostov-on-Don, Russia., Zakharova MN; Research Center of Neurology, Moscow, Russia., Bolsun DD; JSC «BIOCAD», St. Petersburg, Russia., Zinkina-Orikhan AV; JSC «BIOCAD», St. Petersburg, Russia., Lin'kova YN; JSC «BIOCAD», St. Petersburg, Russia., Chernovskaya TV; JSC «BIOCAD», St. Petersburg, Russia., Porozova AA; JSC «BIOCAD», St. Petersburg, Russia.

Publikováno v: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2023; Vol. 123 (2), pp. 52-59.

[Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial].

Autor: Boyko AN; Pirogov National Medical Research University, Moscow, Russia.; Neuro-Clinic (Yusupov Hospital), Moscow, Russia.; Federal Center for Cerebrovascular Pathology and Stroke, Moscow, Russia., Boyko OV; Pirogov National Medical Research University, Moscow, Russia.; Neuro-Clinic (Yusupov Hospital), Moscow, Russia., Bakhtiyarova KZ; Kuvatov Republican Clinical Hospital Ufa, Russi, Kuvatov Republican Clinical Hospital Ufa, Russia., Gusev EI; Pirogov National Medical Research University, Moscow, Russia., Dudin VA; Center for Cardiology and Neurology, Kirov, Russia., Zaslavsky LG; Leningrad Regional Clinical Hospital, St. Petersburg, Russia., Malkova NA; Regional Clinical Hospital, Novosibirsk, Russia., Parshina YV; Semashko Regional Clinical Hospital, Nizhny Novgorod, Russia., Poverennova IY; Seredavin Regional Clinical Hospital, Samara, Russia., Siverceva SA; Medical and Sanitary Unit «Neftyanik», Tyumen, Russia., Totolyan NA; Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russia., Shchur SG; Filatov Moscow City Clinical Hospital No. 15, Moscow, Russia., Fedulov AS; Minsk Research and Development Centre of Surgery, Transplantology and Haematology, Minsk, Republic Belarus., Khabirov FA; Republican Clinical Neurological Center, Kazan, Russia., Bolsun DD; JSC «BIOCAD», St. Petersburg, Russia., Zinkina-Orikhan AV; JSC «BIOCAD», St. Petersburg, Russia., Linkova YN; JSC «BIOCAD», St. Petersburg, Russia., Chernovskaya TV; JSC «BIOCAD», St. Petersburg, Russia.

Publikováno v: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2022; Vol. 122 (1), pp. 62-71.

[Updated recommendations of the Council of Experts on the use and safety of alemtuzumab (Lemtrada)].

Autor: Khachanova NV; Russian National Medical Research University named after N.I. Pirogov, Moscow, Russia., Bakhtiyarova KZ; Medical University of Bashkiriya, Ufa, Russia., Boyko AN; Russian National Medical Research University named after N.I. Pirogov, Moscow, Russia.; Federal Center for Cerebrovascular Pathology and Stroke, Moscow, Russia., Vlasov YV; Samara State Medical University, Samara, Russia., Davydovskaya MV; Russian National Medical Research University named after N.I. Pirogov, Moscow, Russia.; State Budgetary Institution of the Moscow region «Clinical and Economic Analysis Scientific-Practical Center of the Moscow Region Healthcare Ministry, Moscow, Russia., Evdoshenko EP; SPb Centre of Multiple Sclerosis and AID (City Clinical Hospital No31), St. Petersburg, Russia., Zakharova MN; Research Center of Neurology, Moscow, Russia., Kotov SV; State Budgetary Healthcare Institution of Moscow Region Moscow Regional Scientific Research Clinical Institute named after M.F. Vladimirsky, Moscow, Russia., Popova EV; Russian National Medical Research University named after N.I. Pirogov, Moscow, Russia.; Interdistrict Division of Multiple Sclerosis a the 24th City Hospital of Moscow, Moscow, Russia., Sivertseva SA; Tyumen Regional Centre of the Multiple Sclerosis, Tyumen, Russia., Totolyan NA; Federal State Budgetary Educational Institution of Higher Education First Saint Petersburg State Medical University named after Academician I.P. Pavlov of the Ministry of Healthcare of the Russian Federation, Saint Petersburg, Russia., Khabirov FA; Kazan State Medical Academy, Kazan, Russia.

Publikováno v: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2020; Vol. 120 (3), pp. 82-91.

[The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis].

Autor: Evdoshenko EP; SPb Centre of Multiple Sclerosis and AID (City Clinical Hospital №31); St. Petersburg, Russia., Neofidov NA; SPb Centre of Multiple Sclerosis and AID (City Clinical Hospital №31); St. Petersburg, Russia., Bakhtiyarova KZ; Medical University of Bashkiriya, Ufa, Russia., Davydovskaya MV; Pirogov Russian National Research Medical University, Moscow, Russia., Kairbekova EI; SPb Centre of Multiple Sclerosis and AID (City Clinical Hospital №31); St. Petersburg, Russia., Kolontareva YM; 'Novartis Pharma' LLC, Moscow, Russia., Malkova NA; Regional Center of Multiple Sclerosis Novosibirsk Medical State University, Novosibirsk, Russia., Odinak MM; Kirov Military Medical Academy, St. Petersburg, Russia., Popova EV; Pirogov Russian National Research Medical University, Moscow, Russia., Sazonov DV; Siberian District Medical Centre of FMBA of Russia, Novosibirsk, Russia., Stolyarov ID; Bekhtereva Institute of the Human Brain, Russian Academy of Sciences, St. Petersburg, Russia., Smagina IV; Altay Medical State University, Barnaul, Russia ,Kazan State Medical Academy, Kazan, Russia., Fedyanin AS; Altay Medical State University, Barnaul, Russia ,Kazan State Medical Academy, Kazan, Russia., Habirov FA; Kazan State Medical Academy, Kazan, Russia., Khaibullin TI; Kazan State Medical Academy, Kazan, Russia., Khachanova NV; Pirogov Russian National Research Medical University, Moscow, Russia., Shchukin IA; Pirogov Russian National Research Medical University, Moscow, Russia., Boyko AN; Pirogov Russian National Research Medical University, Moscow, Russia.

Publikováno v: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2019; Vol. 119 (10. Vyp. 2), pp. 110-119.